Manufacturer's replyBMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7062.945 (Published 12 October 1996) Cite this as: BMJ 1996;313:945
- Martin C Eagle, Business development manager, oncology
- Orion Pharma (UK), Newbury RG14 5UX
EDITOR,—Naturally we are concerned that Chris Twelves and Adrian Harnett take exception to our advertisement for Fareston (toremifene). Yes, the advertisement focuses on patients' concerns, but are they not relevant? It is not surprising that some women diagnosed as having breast cancer are concerned by what they have read or heard about tamoxifen. Debate in the medical press,1 2 sensationalism in the lay press, and the information superhighway mean that women are …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial